Insmed Announces Pricing of $750 Million Public Offering of Common Stock

Core Viewpoint - Insmed Incorporated has announced a public offering of 7,812,500 shares of common stock at a price of $96.00 per share, aiming to raise approximately $750 million in gross proceeds before expenses [1][2]. Group 1: Offering Details - The public offering is priced at $96.00 per share, with gross proceeds expected to be around $750 million [1]. - Insmed has granted underwriters a 30-day option to purchase an additional 1,171,875 shares [1]. - The offering is expected to close on June 13, 2025, subject to customary closing conditions [3]. Group 2: Use of Proceeds - The net proceeds will be used to fund research and development of brensocatib, pre-commercial and commercialization activities related to brensocatib, and further development of ARIKAYCE® [2]. - Additional funds will support the research and development of treprostinil palmitil inhalation powder (TPIP), INS1201, and other pre-clinical research product candidates, as well as general corporate purposes including business expansion [2]. Group 3: Company Overview - Insmed is a global biopharmaceutical company focused on delivering first- and best-in-class therapies for serious diseases, with a diverse portfolio of approved and investigational medicines [6]. - The company is advancing programs primarily in pulmonary and inflammatory conditions, including a therapy approved in the U.S., Europe, and Japan for a chronic lung disease [6]. - Insmed's research includes a variety of technologies such as gene therapy, AI-driven protein engineering, and synthetic rescue [6].